Momelotinib

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Helena.adamcova (talk | contribs) at 21:53, 2 December 2011 (←Created page with '{{Userspace draft|source=ArticleWizard|date={{Subst:CURRENTMONTHNAME}} {{Subst:CURRENTYEAR}}}} <!-- Please leave this line alone! --> '''CYT387''' is ATP-compet...'). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


CYT387 is ATP-competitive inhibitor of inhibitor of Janus kinases JAK1 and JAK2 with with IC50 values of 11 and 18 nM, respectively. The inhibitor is significantly less active towards other kinases, including JAK3 (IC50 = 0.16 μM).[1]

CYT387 is being developed as a drug for myelofibrosis and currently undergoes Phase I/II clinical trial. Additional potential treatment indications for CYT387 include other myeloproliferative neoplasms, cancer (solid and liquid tumors) and inflammatory conditions.[2]

The drug is developed by YM BioSciences Inc.

References

  1. ^ Leukemia. 2009 Aug;23(8):1441-5.
  2. ^ Leukemia. 2011 Feb;25(2):218-25.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Momelotinib&oldid=463731763"